Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combination therapy with 5% minoxidil and 0.5% anthralin led to hair regrowth in some patients with severe treatment-resistant alopecia areata, but also caused mild to moderate irritant dermatitis in all participants.

In this study, combination therapy with 5% minoxidil and 0.5% anthralin showed some cosmetic improvement in 11% of patients with severe treatment-resistant alopecia areata, with hair regrowth starting by week 12.

This study found that M30 may protect against cyclophosphamide-induced alopecia in mice by enhancing hair growth and preventing abnormal hair, suggesting its potential as a treatment.

Scalp cooling reduces chemotherapy-induced hair loss without increasing risk of skin metastases.

This review article highlights that mesotherapy, a popular non-surgical procedure in aesthetic dermatology, involves injecting a mixture of compounds into the skin for purposes like skin rejuvenation and hair loss treatment, but lacks large-scale studies on its efficacy and safety.

Dermoscopy quickly and accurately diagnosed a rare hair disorder in a 12-year-old girl.

This article reviews interventions for preventing chemotherapy-induced alopecia and highlights scalp cooling as the only currently effective method, while noting its limitations and other potential options without providing new results.

In this study, researchers found that topical application of 3-β-methoxy-Δ18-oleanene (miliacin) in mice sped up the recovery of hair follicles damaged by cyclophosphamide, moving them into a new hair growth cycle more quickly compared to controls.

This study retrospectively observed that combining microneedle minoxidil with triamcinolone acetonide showed clinical efficacy in treating alopecia areata, a condition marked by sudden patchy hair loss.

This review discusses the lack of adequate clinical trials evaluating the efficacy and safety of mesotherapy for cosmetic hair loss and reports no new results.

In this pilot study, researchers found that ex vivo treatment with topical melatonin reduced chemotherapy-induced apoptosis and DNA damage in hair follicle stem cells of human scalp cultures, suggesting melatonin's potential as a protective agent against taxane-induced permanent hair loss.

This study found that minoxidil prevents long-term serotonergic toxicity induced by MDMA in rats, primarily by opening mitochondrial KATP channels and involving Akt and MAP kinases in its neuroprotective mechanism.

This commentary reviews the controversial use of mesotherapy for androgenetic alopecia and emphasizes the need for documented evidence, without reporting new clinical results.

This review compares mesotherapy and PRP for hair loss but reports no new clinical results; the authors highlight the need to understand their differences for optimal treatment choices.

This study found that the PVP protocol, combining Peptichemio, vincristine, and 6-methylprednisolone, resulted in remission for diffuse non-Hodgkin's lymphomas with moderate side effects.

In this case study, a 14-year-old female with premature hair graying showed improved hair color after treatment with a topical Melitane 5% formulation and oral hair supplements.

This case report describes a man with metastatic thymoma and diffuse pleural dissemination mimicking malignant mesothelioma, who also had alopecia areata without the presence of myasthenia gravis.

This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

This study described a novel three-dimensional-printed microneedle system designed for improved transdermal delivery of minoxidil to treat hair loss, demonstrating effective hair regrowth and safety in a mouse model while allowing sustainable needle base recovery.

This study on androgenetic alopecia in mice introduced a novel therapy combining microneedle patches and cold atmospheric plasma to enhance minoxidil delivery, leading to improved hair regeneration by boosting vascular growth and reshaping the hair follicle microenvironment.

This study observed that a mesotherapy formulation was associated with statistically significant improvements in hair quantity, thickness, and scalp condition among 23 patients with androgenetic alopecia, without noted side effects.

In this prospective study, 15 patients with patchy alopecia areata treated with intralesional methotrexate every two weeks showed a significant improvement in hair regrowth and reduction in lesion severity, with changes linked to decreased tissue levels of TNF-α.

This case study reported a 23-year-old woman with chronic myeloid leukemia who developed permanent hair loss after chemotherapy and did not respond to topical minoxidil treatment.

This study suggests that oral zinc sulphate may be an effective and safe treatment for thallium poisoning, particularly in improving dermatological symptoms and reducing the progression of the condition.

This case study reports a 44-year-old man with criminal sublethal thallium poisoning who demonstrated diminished contrast sensitivity, a tritan color vision defect, and a relative cecocentral scotoma leading to optic atrophy.

This position paper from the Italian Mesotherapy Society discusses the application of intradermal therapy based on scientific evidence, highlighting its potential benefits for certain localized conditions, although it acknowledges the lack of randomized clinical trials for some uses.

This study reported that low dose oral minoxidil may help treat persistent chemotherapy-induced alopecia, based on a retrospective case series involving 15 patients across multiple centers.

This study synthesized and characterized new 2-hydroxypyrrolidine/piperidine derivatives using FeCl₃·6H₂O as a catalyst, but it reports no biological or clinical results.

In this study, a novel liposomal peptide formulation significantly enhanced hair growth in mice compared to minoxidil, but results on human tissue penetration were inconclusive, suggesting further research is needed for translation to human use.

This case report describes a three-year-old girl with a two-year history of hair loss who was previously treated with selenium sulfide shampoo, with no family history of alopecia.